We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Exosome Diagnostics to Validate Life Technologies Platform for Biofluid Isolation Kits

By LabMedica International staff writers
Posted on 19 Jun 2012
Print article
Exosome Diagnostics (New York, NY, USA) has reached an agreement with Life Technologies (Carlsbad, CA, USA) to use the Applied Biosystems (ABI) 7500 fast Dx real-time polymerase chain reaction (PCR) instrument for the company’s exosome biofluid in vitro diagnostics oncology program. Exosome Diagnostics plans to validate the ABI instrument platform with exosome biofluid RNA isolation technology kits in multicenter clinical trials in brain and prostate cancer beginning in 2012.

The ABI 7500 fast Dx real-time PCR instrument is one of the most widely distributed PCR platforms in laboratories worldwide and is cleared by the Food and Drug Administration (FDA; Silver Spring, MD, USA).

Exosome Diagnostics is developing a series of urine and blood-based molecular diagnostic tests for use in cancer detection and monitoring. The company's technology can isolate a highly pure, stable preparation of ribonucleic acids from biofluids for analysis on existing analytical platforms such as real time quantitative PCR (qPCR) and next-generation sequencing. The company is partnering with various manufacturing groups to provide branded, original equipment manufacturer (OEM) in vitro diagnostic solutions for regulatory approval and use in the its good laboratory practice (GLP) clinical laboratory improvements amendments (CLIA)-certified laboratory.

"This agreement with Life Technologies continues our pursuit of best-in-class partnerships that include the Prostate Cancer Foundation, Accelerate Brain Cancer Cure and the broad group of leading clinical investigators now collaborating on exosome technology," said James McCullough, CEO of Exosome Diagnostics. "Life Technologies is leading the way in personalized medicine and provides us with the type of customer service and robust technology that are prerequisites to the successful launch of innovative molecular diagnostics."

Related Links:

Exosome Diagnostics
Life Technologies
Food and Drug Administration



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.